13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001848809
Total reported value
$164.2M
$164.2M
45 檔
49.5%
The Q4 2024 SEC filing reveals that Velan Capital Investment Management LP held a total portfolio value of $164.2M, covering 45 public equity positions.
In Q4 2024, Velan Capital Investment Management LP displayed an active expansion posture, initiating 32 new positions and adding to 4 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | JSPR | Jasper Therapeutics Inc | Stock-Other | 26.45% | -0.78% | — | |
| 2 | PRAX | Praxis Precision Medicines I | Stock-Other | 19.92% | -2.24% | -14.45% | |
| 3 | HRTX | Heron Therapeutics Inc | Stock-Other | 9.22% | -2.11% | — | |
| 4 | TRML | Tourmaline Bio Inc | Stock-Other | 7.42% | — | +27.96% | |
| 5 | TARA | Protara Therapeutic Inc | Stock-Other | 7.19% | -2.63% | +175.09% | |
| 6 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 5.78% | — | — | |
| 7 | RZLT | Rezolute Inc | Stock-Other | 3.38% | +0.95% | — | |
| 8 | LQDA | Liquidia CORP | Stock-Other | 3.04% | — | — | |
| 9 | ZVRA | Zevra Therapeutics Inc | Stock-Other | 2.16% | — | +50.00% | |
| 10 | NSPR | Inspiremd Inc | Stock-Other | 2.05% | -2.08% | — | |
| 11 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 2.00% | — | — | |
| 12 | REPL | Replimune Group Inc | Stock-Other | 1.90% | +0.03% | — | |
| 13 | NRIX | Nurix Therapeutics Inc | Stock-Other | 1.59% | +0.08% | — | |
| 14 | CATX | Perspective Therapeutics Inc | Stock-Other | 1.38% | — | — | |
| 15 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 1.15% | — | — | |
| 16 | KURA | Kura Oncology Inc | Stock-Other | 1.13% | — | — | |
| 17 | COLL | Collegium Pharmaceutical Inc | Stock-Other | 0.71% | — | — | |
| 18 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.71% | +1.92% | — | |
| 19 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.58% | — | +13.40% | |
| 20 | TENX | Tenax Therapeutics Inc | Stock-Other | 0.45% | -0.36% | — | |
| 21 | KPRX | Kiora Pharmaceuticals Inc | Stock-Other | 0.35% | — | — | |
| 22 | GERN | Geron CORP | Stock-Other | 0.15% | — | — | |
| 23 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.14% | — | — | |
| 24 | RGLS | Regulus Therapeutics Inc | Stock-Other | 0.10% | — | — | |
| 25 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 0.09% | — | — | |
| 26 | ALEC | Alector Inc | Stock-Other | 0.09% | — | — | |
| 27 | CNTX | Context Therapeutics Inc | Stock-Other | 0.08% | -0.14% | -93.03% | |
| 28 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 0.08% | — | — | |
| 29 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.07% | — | — | |
| 30 | ENTA | Enanta Pharmaceuticals Inc | Stock-Other | 0.06% | — | — | |
| 31 | LRMR | Larimar Therapeutics Inc | Stock-Other | 0.06% | -0.03% | — | |
| 32 | GOSS | Gossamer Bio Inc | Stock-Other | 0.06% | — | — | |
| 33 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 0.06% | — | — | |
| 34 | OVID | Ovid Therapeutics Inc | Stock-Other | 0.06% | -0.01% | — | |
| 35 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 0.05% | — | — | |
| 36 | STRO | Sutro Biopharma, Inc. | Stock-Other | 0.05% | — | — | |
| 37 | PMVP | Pmv Pharmaceuticals Inc | Stock-Other | 0.05% | -0.06% | EXIT | |
| 38 | FGENEUR | Fibrogen Inc | Stock-Other | 0.04% | — | — | |
| 39 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 0.03% | -1.32% | — | |
| 40 | KRON1USD | Kronos Bio Inc | Stock-Other | 0.03% | — | — | |
| 41 | KPTIEUR | Karyopharm Therapeutics Inc | Stock-Other | 0.02% | — | — | |
| 42 | BOLT1EUR | Bolt Biotherapeutics Inc | Stock-Other | 0.02% | — | — | |
| 43 | ✓ | Elevation Oncology Inc | Stock-Other | 0.02% | — | — | |
| 44 | COCP | Cocrystal Pharma Inc | Stock-Other | 0.02% | — | — | |
| 45 | NXTCEUR | Nextcure Inc | Stock-Other | 0.02% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | TARA | Protara Therapeutic Inc | +6.2% | +175.09% | Add |
| 2 | SWTXUSD | Springworks Therapeutics Inc | +5.8% | NEW | New buy |
| 3 | VRNA | Verona Pharma PLC - Adr | +2% | NEW | New buy |
| 4 | REPL | Replimune Group Inc | +1.9% | NEW | New buy |
| 5 | NRIX | Nurix Therapeutics Inc | +1.6% | NEW | New buy |
| 6 | CATX | Perspective Therapeutics Inc | +1.4% | NEW | New buy |
| 7 | JSPR | Jasper Therapeutics Inc | +1.2% | — | Unchanged |
| 8 | ELDN | Eledon Pharmaceuticals Inc | +1.2% | NEW | New buy |
| 9 | KURA | Kura Oncology Inc | +1.1% | NEW | New buy |
| 10 | PRAX | Praxis Precision Medicines I | +1.1% | -14.45% | Trim |
| 11 | ZVRA | Zevra Therapeutics Inc | +0.9% | +50.00% | Add |
| 12 | COLL | Collegium Pharmaceutical Inc | +0.7% | NEW | New buy |
| 13 | AVTX | Avalo Therapeutics Inc | +0.7% | NEW | New buy |
| 14 | LQDA | Liquidia CORP | +0.2% | — | Unchanged |
| 15 | TENX | Tenax Therapeutics Inc | +0.2% | — | Unchanged |
| 16 | GERN | Geron CORP | +0.2% | NEW | New buy |
| 17 | WVE | Wave Life Sciences Ltd. | +0.1% | NEW | New buy |
| 18 | RGLS | Regulus Therapeutics Inc | +0.1% | NEW | New buy |
| 19 | ✓ | Proqr Therapeutics N.v. | +0.1% | NEW | New buy |
| 20 | ALEC | Alector Inc | +0.1% | NEW | New buy |
| 21 | 430 | Terns Pharmaceuticals Inc | +0.1% | NEW | New buy |
| 22 | VTYXUSD | Ventyx Biosciences Inc | +0.1% | NEW | New buy |
| 23 | ENTA | Enanta Pharmaceuticals Inc | +0.1% | NEW | New buy |
| 24 | LRMR | Larimar Therapeutics Inc | +0.1% | NEW | New buy |
| 25 | GOSS | Gossamer Bio Inc | +0.1% | NEW | New buy |
| 26 | ACRS | Aclaris Therapeutics Inc | +0.1% | NEW | New buy |
| 27 | OVID | Ovid Therapeutics Inc | +0.1% | NEW | New buy |
| 28 | FDMT | 4d Molecular Therapeutics In | +0.1% | NEW | New buy |
| 29 | STRO | Sutro Biopharma, Inc. | +0.1% | NEW | New buy |
| 30 | PMVP | Pmv Pharmaceuticals Inc | +0.1% | NEW | New buy |
| 31 | FGENEUR | Fibrogen Inc | 0% | NEW | New buy |
| 32 | CTMX | Cytomx Therapeutics Inc | 0% | NEW | New buy |
| 33 | KRON1USD | Kronos Bio Inc | 0% | NEW | New buy |
| 34 | KPTIEUR | Karyopharm Therapeutics Inc | 0% | NEW | New buy |
| 35 | BOLT1EUR | Bolt Biotherapeutics Inc | 0% | NEW | New buy |
| 36 | ✓ | Elevation Oncology Inc | 0% | NEW | New buy |
| 37 | COCP | Cocrystal Pharma Inc | 0% | NEW | New buy |
| 38 | NXTCEUR | Nextcure Inc | 0% | NEW | New buy |
| 39 | KPRX | Kiora Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 40 | NSPR | Inspiremd Inc | -0.2% | — | Unchanged |
| 41 | RZLT | Rezolute Inc | -0.3% | — | Unchanged |
| 42 | CRBP | Corbus Pharmaceuticals Holdi | -0.4% | +13.40% | Add |
| 43 | TRML | Tourmaline Bio Inc | -0.5% | +27.96% | Add |
| 44 | SKYE | Skye Bioscience Inc | -0.8% | EXIT | Sold out |
| 45 | ✓ | Optinose Inc | -1.3% | EXIT | Sold out |
| 46 | TELA | Tela Bio Inc | -1.8% | EXIT | Sold out |
| 47 | SCPH | Scpharmaceuticals Inc | -2.2% | EXIT | Sold out |
| 48 | CNTX | Context Therapeutics Inc | -2.3% | -93.03% | Trim |
| 49 | HRTX | Heron Therapeutics Inc | -3.8% | — | Unchanged |
| 50 | XBI | Ss Spdr S&p Biotech ETF | -13.9% | EXIT | Sold out |
According to official SEC Form 13F filings, Velan Capital Investment Management LP reported a total U.S. public equity portfolio value of $164.2M across 45 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including JSPR, PRAX, HRTX) accounted for 49.5% of total reported equity market value during Q4 2024.
Top New Position Initiated
SWTXUSD
市值: $6.7M
Top Position Liquidated / Trimmed
XBI
前期市值: $14.8M
During Q4 2024, Velan Capital Investment Management LP's top holdings by market value included JSPR (26.4%)、PRAX (19.9%)、HRTX (9.2%). The largest single position, JSPR, represented 26.4% of total portfolio value.
In Q4 2024, Velan Capital Investment Management LP made 43 total portfolio adjustments, initiating 32 new buys, adding to 4 positions, trimming 2 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.